Single Nucleotide Polymorphism (SNP) Genotyping Global Market Report 2024

The single nucleotide polymorphism (snp) genotyping market size has grown exponentially in recent years. It will grow from $8.48 billion in 2023 to $10.24 billion in 2024 at a compound annual growth rate (CAGR) of 20.7%. The expansion during the historical period can be attributed to increasing research in genomics, a rise in genetic disorders, growth in personalized medicine, the expanding pharmaceutical industry, and rising demand for molecular diagnostics.

The single nucleotide polymorphism (snp) genotyping market size is expected to see rapid growth in the next few years. It will grow to $20.6 billion in 2028 at a compound annual growth rate (CAGR) of 19.1%. The anticipated growth in the forecast period can be attributed to growing applications in disease research, a rise in demand for precision medicine, expanding biobanking initiatives, a surge in genetic testing, and rising adoption in agriculture for crop improvement. Key trends expected in the forecast period include the increasing use of next-generation sequencing (NGS), rising demand for SNP genotyping in pharmacogenomics, the emergence of direct-to-consumer genetic testing, and a focus on automation and high-throughput genotyping platforms.

The growth of the single nucleotide polymorphism (SNP) genotyping market is anticipated to be driven by the increasing burden of chronic conditions. Chronic conditions, defined as ailments lasting a year or more and requiring ongoing medical care, significantly impact daily activities. Single Nucleotide Polymorphism (SNP) genotyping plays a crucial role in identifying genetic predispositions, contributing to the rise of personalized medicine amidst the growing prevalence of chronic diseases. As indicated by the National Center for Biotechnology Information (NCBI) in January 2023, the global number of individuals with chronic diseases is projected to reach 142.66 million by 2050, up from 71.522 million in 2020. This escalation in the burden of chronic conditions is a key factor propelling the growth of the single nucleotide polymorphism (SNP) genotyping systems market.

The increasing allocation of funds for genomic research is poised to further boost the growth of the single nucleotide polymorphism (SNP) genotyping market. Funds for genomic research encompass financial resources dedicated to supporting research activities in genomics, crucial for advancing SNP studies. Organizations such as the National Human Genome Research Institute received $604 million in 2020, $614 million in 2021, and $616 million in 2022, with a proposed budget of $629 million for 2023. Additionally, the Biden administration allocated $1.7 billion in April 2021 to enhance SARS-CoV-2 variant detection, monitoring, and mitigation, emphasizing the establishment of genomic sequencing infrastructure. This rise in funds for genomic research is a significant driver of the single nucleotide polymorphism (SNP) genotyping market.

A prominent trend in the single nucleotide polymorphism (SNP) genotyping market is the adoption of technological solutions. Major companies in this market are introducing advanced solutions to maintain their market position. For instance, in May 2022, Neogen Corporation and Gencove launched InfiniSEEK, the first complete genome and genotyping tool for cattle breeders. InfiniSEEK's validation demonstrates high concordance with deep whole-genome sequencing, providing clinical-grade accuracy in specific areas of interest. This technological advancement underscores the commitment of companies to bring innovative solutions to the single nucleotide polymorphism (SNP) genotyping market.

Companies in the single nucleotide polymorphism (SNP) genotyping market are also focusing on developing biomarkers for coronary heart disease detection, enhancing market profitability. Single nucleotide polymorphism (SNP) biomarkers associated with coronary heart disease (CHD) detection are genetic variations linked to an increased risk of CHD. For instance, Cardio Diagnostics launched PrecisionCHD in February 2023, an AI-driven blood test utilizing epigenetic and genetic biomarkers to detect CHD. This non-invasive test eliminates the need for traditional methods, providing objectivity through biomarkers rather than self-reported patient data.

In July 2021, DiaSorin S.p.A. acquired Luminex Corporation for approximately $1.8 billion. This strategic move aims to broaden the applications of Luminex across the Life Science sector, strengthening collaboration with the biopharmaceutical industry and enhancing the availability of clinical multiplexing assays. Luminex Corporation, a US-based biotechnology company, specializes in single nucleotide polymorphism (SNP) genotyping technology.

Major companies operating in the single nucleotide polymorphism (snp) genotyping market report are Thermo Fisher Scientific Inc., Danaher Corporation, Roche Diagnostics Corporation, GE HealthCare Technologies Inc., Eurofins Genomics LLC, Beckman Coulter Inc., Bio-Rad Laboratories Inc., Qiagen N.V., Sigma-Aldrich Corporation, Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Promega Corporation, GenScript Biotech Corporation, Integrated DNA Technologies Inc., LGC Ltd., Sequenom Inc., Fluidigm Corporation, Agendia Inc., Nugen Technologies Inc., BioChain Institute Inc., Standard BioTools Inc., Oxford Gene Technology, Affymetrix Inc., PREMIER Biosoft International Inc., GenoLogics, Rubicon Genomics Inc., Xcelris Genomics, Douglas Scientific LLC, Golden Helix Inc.

North America was the largest region in the single nucleotide polymorphism (SNP) genotyping market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the single nucleotide polymorphism (snp) genotyping market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the single nucleotide polymorphism (snp) genotyping market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The primary products of single nucleotide polymorphism (SNP) genotyping include consumables, instruments, and services. Consumables refer to items that people and businesses regularly consume or use up, requiring replacement, such as food and home supplies. Various technologies are employed in SNP genotyping, including TaqMan SNP genotyping, Mass Array SNP genotyping, SNP gene chip arrays, and others. These technologies find applications in diverse fields such as animal genetics, plant improvement, diagnostic research, pharmaceuticals and pharmacogenomics, agricultural biotechnology, and more.

The single nucleotide polymorphism (SNP) genotyping market research report is one of a series of new reports that provides single nucleotide polymorphism (SNP) genotyping market statistics, including the single nucleotide polymorphism (SNP) genotyping industry's global market size, regional shares, competitors with a single nucleotide polymorphism (SNP) genotyping market share, detailed single nucleotide polymorphism (SNP) genotyping market segments, market trends and opportunities, and any further data you may need to thrive in the single nucleotide polymorphism (SNP) genotyping industry. This single nucleotide polymorphism (SNP) genotyping market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The single nucleotide polymorphism (SNP) genotyping market includes revenues earned by providing sample collection, DNA extraction, high-resolution melting analysis, and related next-generation sequencing. The market value includes the value of related goods sold by the service provider or included within the service offering. The single nucleotide polymorphism (SNP) genotyping market consists of sales of mass spectrometry-based SNP genotyping and allele-specific PCR. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).


The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.